Research programme: selective androgen receptor modulators - Radius Health

Drug Profile

Research programme: selective androgen receptor modulators - Radius Health

Alternative Names: RAD-140

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Radius
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer
  • No development reported Muscular atrophy; Osteoporosis

Most Recent Events

  • 04 Nov 2016 Radius plans a trial in Breast cancer in USA
  • 04 Aug 2016 Preclinical pharmacodynamics data in Breast cancer released by Radius
  • 17 Nov 2015 Preclinical trials in Breast cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top